Mr. Paul (for himself, Mr. Lee, and Ms. Hassan) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions, Reported by Mr. Cassidy, with an amendment
To amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. Senate. Expedited Access to Biosimilars Act. S. 1414. 119th
Cong., 2nd
sess., Reported in Senate July 27, 2026. https://www.govinfo.gov/app/details/BILLS-119s1414rs.
APA
Congress, Senate (2026, July 27). Expedited Access to Biosimilars Act (S. 1414 (RS)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119s1414rs.
MLA
United States, Congress, Senate. Expedited Access to Biosimilars Act. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119s1414rs. 119th Congress, S. 1414, Reported in Senate 27 Jul. 2026.
Bluebook
S.1414 - 119th Congress (2025-2026): Expedited Access to Biosimilars Act, S.1414, 119th Cong. (2026), https://www.govinfo.gov/app/details/BILLS-119s1414rs.
